Reducing the environmental impact of surgery on a global scale: systematic review and co-prioritization with healthcare workers in 132 countries

Background Healthcare cannot achieve net-zero carbon without addressing operating theatres. The aim of this study was to prioritize feasible interventions to reduce the environmental impact of operating theatres. Methods This study adopted a four-phase Delphi consensus co-prioritization methodology. In phase 1, a systematic review of published interventions and global consultation of perioperative healthcare professionals were used to longlist interventions. In phase 2, iterative thematic analysis consolidated comparable interventions into a shortlist. In phase 3, the shortlist was co-prioritized based on patient and clinician views on acceptability, feasibility, and safety. In phase 4, ranked lists of interventions were presented by their relevance to high-income countries and low–middle-income countries. Results In phase 1, 43 interventions were identified, which had low uptake in practice according to 3042 professionals globally. In phase 2, a shortlist of 15 intervention domains was generated. In phase 3, interventions were deemed acceptable for more than 90 per cent of patients except for reducing general anaesthesia (84 per cent) and re-sterilization of ‘single-use’ consumables (86 per cent). In phase 4, the top three shortlisted interventions for high-income countries were: introducing recycling; reducing use of anaesthetic gases; and appropriate clinical waste processing. In phase 4, the top three shortlisted interventions for low–middle-income countries were: introducing reusable surgical devices; reducing use of consumables; and reducing the use of general anaesthesia. Conclusion This is a step toward environmentally sustainable operating environments with actionable interventions applicable to both high– and low–middle–income countries

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

BACKGROUND: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. METHODS: This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. FINDINGS: Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0-75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4-97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8-80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3-4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. INTERPRETATION: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials. FUNDING: UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D'Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Background A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. Methods This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. Findings Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0–75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4–97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8–80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3–4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. Interpretation ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials

Measurement of D+(s) and D*+(s) production in B meson decays and from continuum e+ e- annihilations at s**(1/2) = 10.6-GeV.

none622Bernard Aubert; D. Boutigny; J.M. Gaillard; A. Hicheur; Y. Karyotakis; J.P. Lees; P. Robbe; V. Tisserand; A. Palano; G.P. Chen; J.C. Chen; N.D. Qi; G. Rong; P. Wang; Y.S. Hz; G. Eigen; P.L. Reinertsen; B. Stugu; B. Abbott; G.S. Abrams; A.W. Borgland; A.B. Breon; David Nathan Brown; Janice Button-Shafer; R.N. Cahn; A.R. Clark; M.S. Gill; A.V. Gritsan; Y. Groysman; R.G. Jacobsen; R.W. Kadel; J. Kadyk; L.T. Kerth; S. Kluth; Yu.G. Kolomensky; J.F. Kral; C. LeClerc; M.E. Levi; T. Liu; G. Lynch; A.B. Meyer; M. Momayezi; P.J. Oddone; A. Perazzo; M. Pripstein; N.A. Roe; A. Romosan; M.T. Ronan; V.G. Shelkov; A.V. Telnov; W.A. Wenzel; P.G. Bright-Thomas; T.J. Harrison; C.M. Hawkes; D.J. Knowles; S.W. O'Neale; R.C. Penny; A.T. Watson; N.K Watson; T. Deppermann; K. Goetzen; H. Koch; J. Krug; M. Kunze; B. Lewandowski; K. Peters; H. Schmuecker; M. Steinke; J.C. Andress; N.R. Barlow; W. Bhimji; N. Chevalier; P.J. Clark; W.N. Cottingham; N. De Groot; N. Dyce; B. Foster; J.D. McFall; D. Wallom; F.F. Wilson; K. Abe; C. Hearty; T.S. Mattison; J.A. McKenna; D. Thiessen; S. Jolly; A.K. McKemey; Jane S. Tinslay; V.E. Blinov; A.D. Bukin; D.A. Bukin; A.R. Buzykaev; V.B. Golubev; V.N. Ivanchenko; A.A. Korol; E.A. Kravchenko; A.P. Onuchin; A.A. Salnikov; S.I. Serednyakov; Yu.I. Skovpen; Valery I. Telnov; A.N. Yushkov; D. Best; A.J. Lankford; M. Mandelkern; S. McMahon; D.P. Stoker; A. Ahsan; K. Arisaka; C. Buchanan; S. Chun; J.G. Branson; D.B. MacFarlane; Soeren A. Prell; S. Rahatlou; G. Raven; V. Sharma; C. Campagnari; B. Dahmes; P.A. Hart; N. Kuznetsova; S.L. Levy; O. Long; A. Lu; J.D. Richman; W. Verkerke; Michael S. Witherell; S. Yellin; J. Beringer; D.E. Dorfan; A.M. Eisner; A. Frey; A.A. Grillo; M. Grothe; C.A. Heusch; R.P. Johnson; W. Kroeger; William S. Lockman; T. Pulliam; H. Sadrozinski; T. Schalk; R.E. Schmitz; B.A. Schumm; A. Seiden; M. Turri; W. Walkowiak; D.C. Williams; M.G. Wison; E. Chen; G.P. Dubois-Felsmann; A. Dvoretskii; D.G. Hitlin; S. Metzler; J. Oyang; F.C. Porter; A. Ryd; A. Samuel; M. Weaver; S. Yang; R.Y. Zhu; S. Devmal; T.L. Geld; S. Jayatilleke; G. Mancinelli; B.T. Meadows; M.D. Sokoloff; T. Barillari; P. Bloom; M.O. Dima; S. Fahey; William T. Ford; D.R. Johnson; U. Nauenberg; A. Olivas; H. Park; P. Rankin; J. Roy; S. Sen; James G. Smith; W.C. van Hoek; D.L. Wagner; J. Blouw; John L. Harton; M. Krishnamurthy; A. Soffer; W.H. Toki; R.J. Wilson; J. Zhang; T. Brandt; J. Brose; T. Colberg; G. Dahlinger; M. Dickopp; R.S. Dubitzky; A. Hauke; E. Maly; R. Muller-Pfefferkorn; S. Otto; Klaus R. Schubert; R. Schwierz; B. Spaan; L. Wilden; L. Behr; Denis Bernard; 1; G.R. Bonneaud; F. Brochard; J. Cohen-Tanugi; S. Ferrag; E. Roussot; S. T'Jampens; C. Thiebaux; G. Vasileiadis; M. Verderi; A. Anjomshoaa; R. Bernet; A. Khan; D. Lavin; F. Muheim; S. Playfer; J.E. Swain; M. Falbo; C. Borean; C. Bozzi; S. Dittongo; M. Folegani; L. Piemontese; E. Treadwell; F. Anulli; R. Baldini-Ferroli; A. Calcaterra; R. de Sangro; D. Falciai; G. Finocchiaro; P. Patteri; I.M. Peruzzi; M. Piccolo; Y. Xie; A. Zallo; S. Bagnasco; A. Buzzo; R. Contri; G. Crosetti; P. Fabbricatore; S. Farinon; M. Lo Vetere; M. Macri; M.R. Monge; R. Musenich; M. Pallavicini; R. Parodi; S. Passaggio; F.C. Pastore; C. Patrignani; M.G. Pia; C. Priano; E. Robutti; A. Santroni; M. Morii; R. Bartoldus; T. Dignan; R. Hamilton; U. Mallik; J. Cochran; H.B. Crawley; P.A. Fischer; J. Lamsa; W.T. Meyer; E.I. Rosenberg; M. Benkebil; G. Grosdidier; C. Hast; Andreas Hocker; H.M. Lacker; S. Laplace; V. Lepeltier; A.M. Lutz; S. Plaszczynski; M.H. Schune; S. Trincaz-Duvoid; A. Valassi; G. Wormser; R.M. Bionta; V. Brigljevic; D.J. Lange; M. Mugge; X. Shi; K. van Bibber; T.J. Wenaus; D.M. Wright; C.R. Wuest; M. Carroll; J.R. Fry; E. Gabathuler; R. Gamet; M. George; M. Kay; D.J. Payne; R.J. Sloane; C. Touramanis; M.L. Aspinwall; D.A. Bowerman; Paul D. Dauncey; U. Egede; Ivo M. Gough Eschrich; N.J.W. Gunawardane; J.A. Nash; P. Sanders; D. Smith; D.E. Azzopardi; J.J. Back; P. Dixon; P.F. Harrison; R.J.L. Potter; H.W. Shorthouse; P. Strother; P.B. Vidal; M.I. Williams; G. Cowan; S. George; M.G. Green; A. Kurup; C.E. Marker; P. McGrath; T.R. McMahon; S. Ricciardi; F. Salvatore; I. Scott; G. Vaitsas; David Norvil Brown; C.L. Davis; John Allison; Roger J. Barlow; J.T. Boyd; A.C. Forti; J. Fullwood; F. Jackson; G.D. Lafferty; N. Savvas; E.T. Simopoulos; J.H. Weatherall; A. Farbin; A. Jawahery; V. Lillard; J. Olsen; D.A. Roberts; J.R. Schieck; G. Blaylock; C. Dallapiccola; K.T. Flood; Stanley S. Hertzbach; R. Kofler; T.B. Moore; H. Staengle; Stephane Willocq; B. Brau; R. Cowan; G. Sciolla; F. Taylor; R.K. Yamamoto; M. Milek; P.M. Patel; J. Trischuk; F. Lanni; F. Palombo; J.M. Bauer; M. Booke; L. Cremaldi; V. Eschenburg; R. Kroeger; J. Reidy; D.A. Sanders; D.J. Summers; J.P. Martin; J.Y. Nief; R. Seitz; P. Taras; A. Woch; V. Zacek; H. Nicholson; C.S. Sutton; C. Cartaro; N. Cavallo; G. De Nardo; F. Fabozzi; C. Gatto; L. Lista; P. Paolucci; D. Piccolo; C. Sciacca; J.M. LoSecco; J.R.G. Alsmiller; T.A. Gabriel; T. Handler; J. Brau; R. Frey; M. Iwasaki; N.B. Sinev; David M. Strom; F. Colecchia; F. Dal Corso; A. Dorigo; F. Galeazzi; M. Margoni; G. Michelon; M. Morandin; M. Posocco; M. Rotondo; F. Simonetto; R. Stroili; E. Torassa; C. Voci; Maurice Benayoun; H. Briand; J. Chauveau; P. David; C. de la Vaissiere; L. Del Buono; O. Hamon; F. Le Diberder; P Leruste; J. Lory; L. Roos; J. Stark; S. Versille; P. Manfredi; V. Re; V. Speziali; E.D. Frank; Larry D. Gladney; Q.H. Guo; J.H. Panetta; C. Angelini; G. Batignani; S. Bettarini; M. Bondioli; M. Carpinelli; F. Forti; M.A. Giorgi; A. Lusiani; F. Martinez-Vidal; M. Morganti; N. Neri; E. Paoloni; M. Rama; G. Rizzo; F. Sandrelli; G. Simi; G. Triggiani; J. Walsh; M. Haire; D. Judd; K. Paick; L. Turnbull; D.E. Wagoner; J. Albert; C. Bula; P. Elmer; C. Lu; K.T. McDonald; V. Miftakov; S.F. Schaffner; A.J.S. Smith; A. Tumanov; E.W. Varnes; G. Cavoto; D. del Re; R. Faccini; F. Ferrarotto; F. Ferroni; K. Fratini; E. Lamanna; Emanuele Leonardi; M.A. Mazzoni; Silvio Morganti; G. Piredda; F. Safai Tehrani; M. Serra; C. Voena; S. Christ; R. Waldi; P.F. Jacques; M. Kalelkar; R.J. Plano; T. Adye; B. Franek; N.I. Geddes; G.P. Gopal; S.M. Xella; R. Aleksan; G. De Domenico; S. Emery; A. Gaidot; S.F. Ganzhur; P.F. Giraud; W. Kozanecki; M. Langer; G.W. London; B. Mayer; B. Serfass; G. Vasseur; C. Yeche; M. Zito; N. Copty; M.V. Purohit; H. Singh; F.X. Yumiceva; I. Adam; P.L. Anthony; D. Aston; K. Baird; J.P. Berger; Elliott D. Bloom; A.M. Boyarski; F. Bulos; G. Calderini; R. Claus; M.R. Convery; D.P. Coupal; D.H. Coward; J. Dorfan; M. Doser; W. Dunwoodie; R.C. Field; T. Glanzman; G.L. Godfrey; S.J. Gowdy; P. Grosso; T. Himel; Tetiana Berger-Hryn'ova; M.E. Huffer; Walter R. Innes; C.P. Jessop; M.H. Kelsey; P. Kim; M.L. Kocian; Urs Langenegger; David W.G.S. Leith; S. Luitz; V. Luth; H.L. Lynch; H. Marsiske; S. Menke; R. Messner; K.C. Moffeit; R. Mount; D.R. Muller; C.P. O'Grady; M. Perl; S. Petrak; Helen R. Quinn; B.N. Ratcliff; S.H. Robertson; L.S. Rochester; A. Roodman; T. Schietinger; R.H. Schindler; J. Schwiening; V.V. Serbo; A. Snyder; A. Soha; S.M. Spanier; J. Stelzer; D. Su; M.K. Sullivan; H.A. Tanaka; J. Va'vra; S.R. Wagner; A.J.R. Weinstein; William J. Wisniewski; D.H. Wright; C.C. Young; P.R. Burchat; C.H. Cheng; David P. Kirkby; T.I. Meyer; C. Roat; R. Henderson; W. Bugg; H. Cohn; A.W. Weidemann; J.M. Izen; I. Kitayama; X.C. Lou; m. Turcotte; F. Bianchi; Marcella Bona; B. Di Girolamo; D. Gamba; A. Smol; D. Zanin; L. Bosisio; G. Della Ricca; L. Lanceri; A. Pompili; P. Poropat; M. Prest; E. Vallazza; G. Vuagnin; R.S. Panvini; C. Brown; Asoka S. De Silva; Robert V. Kowalewski; J.M. Roney; H.R. Band; E. Charles; S. Dasu; F. Di Lodovico; A.M. Eichenbaum; H. Hu; J.R. Johnson; R. Liu; J. Nielsen; Y. Pan; R. Prepost; I.J. Scott; J.H. von Wimmersperg-Toeller; S.L. Wu; Z. Yu; H. Zobernig; T.M.B. Kordich; H. NealBernard, Aubert; D., Boutigny; J. M., Gaillard; A., Hicheur; Y., Karyotakis; J. P., Lees; P., Robbe; V., Tisserand; A., Palano; G. P., Chen; J. C., Chen; N. D., Qi; G., Rong; P., Wang; Y. S., Hz; G., Eigen; P. L., Reinertsen; B., Stugu; B., Abbott; G. S., Abrams; A. W., Borgland; A. B., Breon; David Nathan, Brown; Janice Button, Shafer; R. N., Cahn; A. R., Clark; M. S., Gill; A. V., Gritsan; Y., Groysman; R. G., Jacobsen; R. W., Kadel; J., Kadyk; L. T., Kerth; S., Kluth; Kolomensky, Y. u. G.; J. F., Kral; C., Leclerc; M. E., Levi; T., Liu; G., Lynch; A. B., Meyer; M., Momayezi; P. J., Oddone; A., Perazzo; M., Pripstein; N. A., Roe; A., Romosan; M. T., Ronan; V. G., Shelkov; A. V., Telnov; W. A., Wenzel; P. G., Bright Thomas; T. J., Harrison; C. M., Hawkes; D. J., Knowles; S. W., O'Neale; R. C., Penny; A. T., Watson; N. K., Watson; T., Deppermann; K., Goetzen; H., Koch; J., Krug; M., Kunze; B., Lewandowski; K., Peters; H., Schmuecker; M., Steinke; J. C., Andress; N. R., Barlow; W., Bhimji; N., Chevalier; P. J., Clark; W. N., Cottingham; N., De Groot; N., Dyce; B., Foster; J. D., Mcfall; D., Wallom; F. F., Wilson; K., Abe; C., Hearty; T. S., Mattison; J. A., Mckenna; D., Thiessen; S., Jolly; A. K., Mckemey; Jane S., Tinslay; V. E., Blinov; A. D., Bukin; D. A., Bukin; A. R., Buzykaev; V. B., Golubev; V. N., Ivanchenko; A. A., Korol; E. A., Kravchenko; A. P., Onuchin; A. A., Salnikov; S. I., Serednyakov; Skovpen, Y. u. I.; Valery I., Telnov; A. N., Yushkov; D., Best; A. J., Lankford; M., Mandelkern; S., Mcmahon; D. P., Stoker; A., Ahsan; K., Arisaka; C., Buchanan; S., Chun; J. G., Branson; D. B., Macfarlane; Soeren A., Prell; S., Rahatlou; G., Raven; V., Sharma; C., Campagnari; B., Dahmes; P. A., Hart; N., Kuznetsova; S. L., Levy; O., Long; A., Lu; J. D., Richman; W., Verkerke; Michael S., Witherell; S., Yellin; J., Beringer; D. E., Dorfan; A. M., Eisner; A., Frey; A. A., Grillo; M., Grothe; C. A., Heusch; R. P., Johnson; W., Kroeger; William S., Lockman; T., Pulliam; H., Sadrozinski; T., Schalk; R. E., Schmitz; B. A., Schumm; A., Seiden; M., Turri; W., Walkowiak; D. C., Williams; M. G., Wison; E., Chen; G. P., Dubois Felsmann; A., Dvoretskii; D. G., Hitlin; S., Metzler; J., Oyang; F. C., Porter; A., Ryd; A., Samuel; M., Weaver; S., Yang; R. Y., Zhu; S., Devmal; T. L., Geld; S., Jayatilleke; G., Mancinelli; B. T., Meadows; M. D., Sokoloff; T., Barillari; P., Bloom; M. O., Dima; S., Fahey; William T., Ford; D. R., Johnson; U., Nauenberg; A., Olivas; H., Park; P., Rankin; J., Roy; S., Sen; James G., Smith; W. C., van Hoek; D. L., Wagner; J., Blouw; John L., Harton; M., Krishnamurthy; A., Soffer; W. H., Toki; R. J., Wilson; J., Zhang; T., Brandt; J., Brose; T., Colberg; G., Dahlinger; M., Dickopp; R. S., Dubitzky; A., Hauke; E., Maly; R., Muller Pfefferkorn; S., Otto; Klaus R., Schubert; R., Schwierz; B., Spaan; L., Wilden; L., Behr; Denis, Bernard; 1, ; G. R., Bonneaud; F., Brochard; J., Cohen Tanugi; S., Ferrag; E., Roussot; S., T'Jampens; C., Thiebaux; G., Vasileiadis; M., Verderi; A., Anjomshoaa; R., Bernet; A., Khan; D., Lavin; F., Muheim; S., Playfer; J. E., Swain; M., Falbo; C., Borean; C., Bozzi; S., Dittongo; M., Folegani; L., Piemontese; E., Treadwell; F., Anulli; R., Baldini Ferroli; A., Calcaterra; R., de Sangro; D., Falciai; G., Finocchiaro; P., Patteri; I. M., Peruzzi; M., Piccolo; Y., Xie; A., Zallo; S., Bagnasco; A., Buzzo; Contri, Roberto; G., Crosetti; P., Fabbricatore; S., Farinon; LO VETERE, Maurizio; M., Macri; Monge, MARIA ROBERTA; R., Musenich; Pallavicini, Marco; R., Parodi; S., Passaggio; F. C., Pastore; Patrignani, Claudia; M. G., Pia; C., Priano; E., Robutti; Santroni, Alberto; M., Morii; R., Bartoldus; T., Dignan; R., Hamilton; U., Mallik; J., Cochran; H. B., Crawley; P. A., Fischer; J., Lamsa; W. T., Meyer; E. I., Rosenberg; M., Benkebil; G., Grosdidier; C., Hast; Andreas, Hocker; H. M., Lacker; S., Laplace; V., Lepeltier; A. M., Lutz; S., Plaszczynski; M. H., Schune; S., Trincaz Duvoid; A., Valassi; G., Wormser; R. M., Bionta; V., Brigljevic; D. J., Lange; M., Mugge; X., Shi; K., van Bibber; T. J., Wenaus; D. M., Wright; C. R., Wuest; M., Carroll; J. R., Fry; E., Gabathuler; R., Gamet; M., George; M., Kay; D. J., Payne; R. J., Sloane; C., Touramanis; M. L., Aspinwall; D. A., Bowerman; Paul D., Dauncey; U., Egede; Ivo M., Gough Eschrich; N. J. W., Gunawardane; J. A., Nash; P., Sanders; D., Smith; D. E., Azzopardi; J. J., Back; P., Dixon; P. F., Harrison; R. J. L., Potter; H. W., Shorthouse; P., Strother; P. B., Vidal; M. I., Williams; G., Cowan; S., George; M. G., Green; A., Kurup; C. E., Marker; P., Mcgrath; T. R., Mcmahon; S., Ricciardi; F., Salvatore; I., Scott; G., Vaitsas; David Norvil, Brown; C. L., Davis; John, Allison; Roger J., Barlow; J. T., Boyd; A. C., Forti; J., Fullwood; F., Jackson; G. D., Lafferty; N., Savvas; E. T., Simopoulos; J. H., Weatherall; A., Farbin; A., Jawahery; V., Lillard; J., Olsen; D. A., Roberts; J. R., Schieck; G., Blaylock; C., Dallapiccola; K. T., Flood; Stanley S., Hertzbach; R., Kofler; T. B., Moore; H., Staengle; Stephane, Willocq; B., Brau; R., Cowan; G., Sciolla; F., Taylor; R. K., Yamamoto; M., Milek; P. M., Patel; J., Trischuk; F., Lanni; F., Palombo; J. M., Bauer; M., Booke; L., Cremaldi; V., Eschenburg; R., Kroeger; J., Reidy; D. A., Sanders; D. J., Summers; J. P., Martin; J. Y., Nief; R., Seitz; P., Taras; A., Woch; V., Zacek; H., Nicholson; C. S., Sutton; C., Cartaro; N., Cavallo; G., De Nardo; F., Fabozzi; C., Gatto; L., Lista; P., Paolucci; D., Piccolo; C., Sciacca; J. M., Losecco; J. R. G., Alsmiller; T. A., Gabriel; T., Handler; J., Brau; R., Frey; M., Iwasaki; N. B., Sinev; David M., Strom; F., Colecchia; F., Dal Corso; A., Dorigo; F., Galeazzi; M., Margoni; G., Michelon; M., Morandin; M., Posocco; M., Rotondo; F., Simonetto; R., Stroili; E., Torassa; C., Voci; Maurice, Benayoun; H., Briand; J., Chauveau; P., David; C., de la Vaissiere; L., Del Buono; O., Hamon; F., Le Diberder; P., Leruste; J., Lory; L., Roos; J., Stark; S., Versille; P., Manfredi; V., Re; V., Speziali; E. D., Frank; Larry D., Gladney; Q. H., Guo; J. H., Panetta; C., Angelini; G., Batignani; S., Bettarini; M., Bondioli; M., Carpinelli; F., Forti; M. A., Giorgi; A., Lusiani; F., Martinez Vidal; M., Morganti; N., Neri; E., Paoloni; M., Rama; G., Rizzo; F., Sandrelli; G., Simi; G., Triggiani; J., Walsh; M., Haire; D., Judd; K., Paick; L., Turnbull; D. E., Wagoner; J., Albert; C., Bula; P., Elmer; C., Lu; K. T., Mcdonald; V., Miftakov; S. F., Schaffner; A. J. S., Smith; A., Tumanov; E. W., Varnes; G., Cavoto; D., del Re; R., Faccini; F., Ferrarotto; F., Ferroni; K., Fratini; E., Lamanna; Emanuele, Leonardi; M. A., Mazzoni; Silvio, Morganti; G., Piredda; F., Safai Tehrani; M., Serra; C., Voena; S., Christ; R., Waldi; P. F., Jacques; M., Kalelkar; R. J., Plano; T., Adye; B., Franek; N. I., Geddes; G. P., Gopal; S. M., Xella; R., Aleksan; G., De Domenico; S., Emery; A., Gaidot; S. F., Ganzhur; P. F., Giraud; W., Kozanecki; M., Langer; G. W., London; B., Mayer; B., Serfass; G., Vasseur; C., Yeche; M., Zito; N., Copty; M. V., Purohit; H., Singh; F. X., Yumiceva; I., Adam; P. L., Anthony; D., Aston; K., Baird; J. P., Berger; Elliott D., Bloom; A. M., Boyarski; F., Bulos; G., Calderini; R., Claus; M. R., Convery; D. P., Coupal; D. H., Coward; J., Dorfan; M., Doser; W., Dunwoodie; R. C., Field; T., Glanzman; G. L., Godfrey; S. J., Gowdy; P., Grosso; T., Himel; Tetiana Berger, Hryn'Ova; M. E., Huffer; Walter R., Innes; C. P., Jessop; M. H., Kelsey; P., Kim; M. L., Kocian; Urs, Langenegger; David W. G. S., Leith; S., Luitz; V., Luth; H. L., Lynch; H., Marsiske; S., Menke; R., Messner; K. C., Moffeit; R., Mount; D. R., Muller; C. P., O'Grady; M., Perl; S., Petrak; Helen R., Quinn; B. N., Ratcliff; S. H., Robertson; L. S., Rochester; A., Roodman; T., Schietinger; R. H., Schindler; J., Schwiening; V. V., Serbo; A., Snyder; A., Soha; S. M., Spanier; J., Stelzer; D., Su; M. K., Sullivan; H. A., Tanaka; J., Va'Vra; S. R., Wagner; A. J. R., Weinstein; William J., Wisniewski; D. H., Wright; C. C., Young; P. R., Burchat; C. H., Cheng; David P., Kirkby; T. I., Meyer; C., Roat; R., Henderson; W., Bugg; H., Cohn; A. W., Weidemann; J. M., Izen; I., Kitayama; X. C., Lou; M., Turcotte; F., Bianchi; Marcella, Bona; B., Di Girolamo; D., Gamba; A., Smol; D., Zanin; L., Bosisio; G., Della Ricca; L., Lanceri; A., Pompili; P., Poropat; M., Prest; E., Vallazza; G., Vuagnin; R. S., Panvini; C., Brown; Asoka S., De Silva; Robert V., Kowalewski; J. M., Roney; H. R., Band; E., Charles; S., Dasu; F., Di Lodovico; A. M., Eichenbaum; H., Hu; J. R., Johnson; R., Liu; J., Nielsen; Y., Pan; R., Prepost; I. J., Scott; J. H., von Wimmersperg Toeller; S. L., Wu; Z., Yu; H., Zobernig; T. M. B., Kordich; H., Nea

Measurement of the CP violating asymmetry amplitude sin 2beta

We present results on time-dependent CP-violating asymmetries in neutral B decays to several CP eigenstates. The measurements use a data sample of about 88 million Y(4S) --> B Bbar decays collected between 1999 and 2002 with the BABAR detector at the PEP-II asymmetric-energy B Factory at SLAC. We study events in which one neutral B meson is fully reconstructed in a final state containing a charmonium meson and the other B meson is determined to be either a B0 or B0bar from its decay products. The amplitude of the CP-violating asymmetry, which in the Standard Model is proportional to sin2beta, is derived from the decay-time distributions in such events. We measure sin2beta = 0.741 +/- 0.067 (stat) +/- 0.034 (syst) and |lambda| = 0.948 +/- 0.051 (stat) +/- 0.030 (syst). The magnitude of lambda is consistent with unity, in agreement with the Standard Model expectation of no direct CP violation in these modes.Comment: 7 pages, 2 postscript figures, submitted to PR

Improved Measurement of the Cabibbo-Kobayashi-Maskawa Angle α Using B0(B¯)→ρ+ρ- Decays

We present results from an analysis of B0(B̅ 0)→ρ+ρ- using 232×106 Υ(4S)→BB̅ decays collected with the BABAR detector at the PEP-II asymmetric-energy B factory at SLAC. We measure the longitudinal polarization fraction fL=0.978±0.014(stat)+0.021/-0.029(syst) and the CP-violating parameters SL=-0.33±0.24(stat)+0.08/-0.14(syst) and CL=-0.03±0.18(stat)±0.09(syst). Using an isospin analysis of B→ρρ decays, we determine the unitarity triangle parameter α. The solution compatible with the standard model is α=(100±13)°

Improved measurement of the Cabibbo-Kobayashi-Maskawa angle α using B0(B)→p+p- decays

We present results from an analysis of B0(B¯¯¯0)→ρ+ρ− using 232×106 Υ(4S)→BB¯¯¯ decays collected with the BABAR detector at the PEP-II asymmetric-energy B factory at SLAC. We measure the longitudinal polarization fraction fL=0.978±0.014(stat)+0.021−0.029(syst) and the CP-violating parameters SL=−0.33±0.24(stat)+0.08−0.14(syst) and CL=−0.03±0.18(stat)±0.09(syst). Using an isospin analysis of B→ρρ decays, we determine the unitarity triangle parameter α. The solution compatible with the standard model is α=(100±13)°